IXALTIS
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. The company was born out of the combined expertise of scientists specialized in urology, pharmaceutical experts and experienced managers: Dr. Philippe Lluel, Christian Chavy, Stefano Palea, Dr. Roberto Gradnik and Professors Pascal Rischmann and Xavier Gamé. The vision of IXALTIS is to develop treatments for genito-urinary tract diseases with still a high unmet medical need, by identifying drugs which had already reached clinical stage and reexplore these for use in genitourinary tract disorders. IXALTIS has established a proprietary position covering Litoxetine for use in urogenital and other disorders based on its specific mechanism of action.
IXALTIS
Industry:
Biopharma Biotechnology Health Care Medical Medical Device Pharmaceutical Therapeutics
Founded:
2012-01-01
Address:
Toulouse, Midi-Pyrenees, France
Country:
France
Website Url:
http://www.ixaltis.com
Total Employee:
11+
Status:
Active
Contact:
+33 (0)4 57 26 00 76
Email Addresses:
[email protected]
Total Funding:
8 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins IPv6 Google Apps For Business Google Maps
Current Employees Featured
Founder
Investors List
IXO Private Equity
IXO Private Equity investment in Venture Round - Ixaltis
Principia SGR
Principia SGR investment in Venture Round - Ixaltis
Pierre Olivier Goineau
Pierre Olivier Goineau investment in Venture Round - Ixaltis
IRDI
IRDI investment in Venture Round - Ixaltis
Sofimac Investment Managers
Sofimac Investment Managers investment in Venture Round - Ixaltis
Official Site Inspections
http://www.ixaltis.com
- Host name: gpaas2.dc0.gandi.net
- IP address: 217.70.180.132
- Location: Paris France
- Latitude: 48.8543
- Longitude: 2.3527
- Timezone: Europe/Paris
- Postal: 75000
More informations about "Ixaltis"
About us - IXALTIS
IXALTIS is start-up pharmaceutical company specialized in genitourinary and renal diseases.See details»
Ixaltis - Crunchbase Company Profile & Funding
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. The company was born out of the combined expertise of …See details»
Management – IXALTIS
Trained as a physician, Roberto Gradnik has more than 25 years’ experience in the pharmaceutical and biotechnology sector. After holding various positions with the Knoll Group …See details»
Ixaltis Company Profile 2024: Valuation, Funding & Investors
Ixaltis General Information Description. Developer of novel pharmaceutical products designed to treat disorders of the urogenital tract. The company's products include selective serotonin, …See details»
Ixaltis - VentureRadar
IXALTIS is start-up pharmaceutical company specialized in genitourinary and renal diseases. The company was born out of the combined expertise of scientists specialized in urology, …See details»
Ixaltis - Products, Competitors, Financials, Employees, …
About Ixaltis. Ixaltis is a specialty pharmaceutical company focused on developing treatments for genitourinary tract disorders. The company offers innovative pharmaceutical products aimed at …See details»
Ixaltis - Funding, Financials, Valuation & Investors - Crunchbase
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs. Search Crunchbase. ... How much funding has this …See details»
Ixaltis - Contacts, Employees, Board Members, Advisors & Alumni
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs.See details»
IXALTIS Company Profile | TOULOUSE, OCCITANIE, France
Find company research, competitor information, contact details & financial data for IXALTIS of TOULOUSE, OCCITANIE. Get the latest business insights from Dun & Bradstreet.See details»
Ixaltis - Overview, News & Similar companies | ZoomInfo.com
IXALTIS has acquired rights to three molecules, including Litoxetine (IXA-001) under exclusive license from Sanofi. The first pre-clinical trials, conducted by private and academic institutes, …See details»
Board of Directors - IXALTIS
IXO Private Equity (as observer) IXALTIS © 2017 / All Rights ReservedSee details»
Ixaltis gets funds to repurpose drug | C&EN Global Enterprise
Jun 13, 2016 Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm’s pipeline consists of three compounds licensed from …See details»
Ex-Stallergenes CEO grabs €8M to advance Sanofi castoff at ...
Jun 1, 2016 Roberto Gradnik and Christian Chavy, the two aforementioned ex-Stallergenes CEOs, set up Ixaltis a few years ago with the CEO of preclinical CRO Urosphere and a pair of …See details»
Ixaltis - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Ixaltis is a pharmaceutical company that develops therapeutics to treat genitourinary disorders with unsatisfied medical needs.See details»
IXALTIS launches its first clinical study in Europe and Canada
IXALTIS has acquired rights to three molecules, including Litoxetine (IXA-001) under exclusive license from Sanofi. The first pre-clinical trials, conducted by private and academic institutes, …See details»
Contact - IXALTIS
IXALTIS © 2017 / All Rights ReservedSee details»
IXALTIS presents positive results from phase 2 studies for
Oct 2, 2019 Toulouse (31) / Archamps (74),October 1st, 2019 – Ixaltis is pleased to announce that the results from both phase 2 studies for its main compound Litoxetine (LTX) have been …See details»
Press - IXALTIS
Press Release, Ixaltis-Successful Completion of phase 2 for Litoxetine, May 2019 Read More In Press. 09 Juil 2018 29 février 2024. Press Release, Ixaltis-Completion of recruitment in …See details»
Pipeline – IXALTIS
IXALTIS has already in-licensed, with an exclusive worldwide deal, three molecules from SANOFI, Litoxetine, IXA-002, and IXA-003.See details»